Natera Inc

NTRA remains in a Stage 2 uptrend. After an overbought extension, the stock has pulled back and held the rising 9- and 20-day EMAs, offering a favorable buy opportunity. Medium-term bias stays bullish as higher highs and lows persist above the 50-day SMA, while the long-term structure is intact above the 200-day SMA. With momentum indicators cooled and dynamic support confirmed, a buy-now approach is justified, though a break below the 20-day EMA would invalidate this view.

• ↑Q2 2026 revenue of $753M beat estimates by 38% YoY.
• ↑Processed 1,044,000 tests in Q2; MRD volumes rose 56% YoY.
• ↓Valuation at 15.4x revenue vs ~$255 fair value implies stretched price.